5 completed, 2 recruiting, 2 withdrawn, 1 active not recruiting. 13 Phase 2, 4 Phase 1, 1 Phase 3.
Follow ADI-PEG 20: new trials by email Literature Review of ADI-PEG 20 trials Research Report on ADI-PEG 20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-11-09 |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) ADI-PEG 20, Cabazitaxel, Carboplatin - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-02-29 | 2026-09-18 |
| A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma Atezolizumab, Bevacizumab, ADI-PEG 20 - Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-08-08 | 2024-08-26 | |
| ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 31 | 2023-04-05 | 2026-07-27 |
| Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer Nivolumab, Pegargiminase, Resection - Resectable Hepatocellular Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-04-13 | 2023-02-16 | |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme ADI-PEG 20, Temozolomide, Placebo - Glioblastoma Multiforme (GBM) | Phase 2 | Active not recruiting | Polaris Group | 100 | 2020-09-14 | 2025-08-26 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-11-02 |
| ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer pegylated arginine deiminase, Gemcitabine, Docetaxel - Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 98 | 2018-05-09 | 2025-12-11 |
| PH 2 ADI-PEG 20 Acute Myeloid Leukemia ADI-PEG 20 - Acute Myeloid Leukemia | Phase 2 | Completed | Polaris Group | 43 | 2015-01-06 | 2020-10-01 |
| Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma ADI-PEG 20, Transarterial chemoembolization - Unresectable Hepatocellular Carcinoma | Phase 2 | Completed | Polaris Group | 30 | 2014-10-15 | 2018-09-04 |
| PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy ADI-PEG 20 - Non-Hodgkin's Lymphoma | Phase 2 | Completed | Polaris Group | 18 | 2013-12-06 | 2018-09-18 |
| A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma ADI-PEG 20 - Malignant Pleural Mesothelioma | Phase 2 | Unknown | Barts & The London NHS Trust | 70 | 2011-01-01 | 2014-11-20 |
| Testing of ADI-PEG in Hepatocellular Carcinoma ADI-PEG 20 - Carcinoma, Hepatocellular | Phase 2 | Completed | FDA Office of Orphan Products Development | 34 | 2002-09-01 | 2015-03-25 |
Glioblastoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Mesothelioma, Malignant (1) · Prostatic Neoplasms (1) · Recurrence (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
Polaris Group (4) · M.D. Anderson Cancer Center (3) · Washington University School of Medicine (2) · Barts & The London NHS Trust (1) · FDA Office of Orphan Products Development (1) · Global Coalition for Adaptive Research (1) · Sabine Mueller, MD, PhD (1)
United States (9) · Taiwan (4) · Australia (1) · Canada (1) · France (1) · Germany (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Ana Aparicio, MD (1) · Christine Auberle, M.D. (1) · Kuo-Chen Wei, M.D. (1) · Mia Weiss, M.D. (1) · Pei-Jer Chen, MD, PhD (1) · Peter Szlosarek (1) · Sabine Mueller, MD, PhD (1) · Sunyoung Lee (1) · Tim Cloughesy, MD (1) · Tom Davidson, MD (1)
PMID 27584578, PMID 28900115, PMID 38773224, PMID 41980234
R01CA227115 (1)